ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2009
What is the role for donor natural killer cells after nonmyeloablative conditioning?
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.Journal of hematology & oncology · 2015Trial
- Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.American journal of hematology · 2013Trial
- A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Cancer chemotherapy and pharmacology · 2013Trial
- Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- Metabolic instruction of the graft-versus-leukemia immunity.Frontiers in immunology · 2024Review
- Clinically applicable CD34Cancer immunology, immunotherapy : CII · 2021Article
- Review
- The Graft-Versus-Leukemia Effect in AML.Frontiers in oncology · 2019Review
- NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.Blood advances · 2018Article
- Article
- Natural Killer Cells: Development, Maturation, and Clinical Utilization.Frontiers in immunology · 2018Review
- A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.Balkan medical journal · 2017Review
- Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Frontiers in immunology · 2017Review
- Nonmyeloablative allogeneic hematopoietic cell transplantation.Haematologica · 2016Review
- Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Bone marrow transplantation · 2014Article
- Immunotherapeutic approaches to treat multiple myeloma.Human vaccines & immunotherapeutics · 2014Review
- Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?Frontiers in immunology · 2014Review
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We investigated the impacts of the tempo of early (days 14, 28, and 42) donor T cell and natural killer (NK) cell engraftment, missing recipient killer cell immunoglobulin-like receptor (KIR) ligands, and numbers of donor inhibitory and activating KIR genes on hematopoietic cell transplantation (HCT) outcomes in 282 patients with hematologic malignancies given nonmyeloablative conditioning. Modeling chimerism levels as a continuous linear variable, we found that high early donor T cell chimerism was significantly associated with acute graft-versus-host disease (aGVHD) (P = .01), whereas high donor NK cell chimerism levels had no such association (P = .38). Conversely, high donor NK cell chimerism levels were significantly associated with low relapse risk (P = .0009), whereas no significant association was seen with high donor T cell chimerism (P = .10). The qualitative associations between donor T cell and NK cell chimerism levels and GVHD and relapse did not change after adjustment for the presence of recipient KIR ligands or numbers of donor inhibitory or activating KIR genes. Our data indicate that prompt engraftment of donor NK cells correlated with lessened risks of relapse, but not with GVHD, whereas the converse was true for T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.